Rekha Hemrajani
Director/Board Member chez MAXCYTE, INC.
Fortune : 33 450 $ au 31/03/2024
Profil
Rekha Hemrajani currently works at MaxCyte, Inc., as Independent Non-Executive Director from 2021, BioAge Labs, Inc., as Independent Director from 2021, ALX Oncology, Inc., as Director from 2020, Hemmo Pharmaceuticals Pvt Ltd., as Director & Partner, ALX Oncology Holdings, Inc., as Non-Executive Independent Director from 2020, and Hemmo Pharma LLP, as Director & Partner.
Ms. Hemrajani also formerly worked at Aravive, Inc., as President, Chief Executive Officer & Director in 2020, Jiya Acquisition Corp., as Chief Executive Officer & Director from 2020 to 2022, Adverum Biotechnologies, Inc., as Independent Director from 2019 to 2021, Lehman Brothers, Inc., as Vice President, Onyx Pharmaceuticals, Inc., as VP & Head-Licensing, Mergers & Acquisitions from 2012 to 2013, Exelixis, Inc., as Vice President-Business Development from 2003 to 2011, Sagimet Biosciences, Inc., as CFO, SVP-Business & Financial Operations from 2015 to 2016, Rapt Therapeutics, Inc., as Chief Operating Officer from 2016 to 2019, and Arcus Biosciences, Inc., as Chief Operating & Financial Officer in 2019.
Ms. Hemrajani received her undergraduate degree from the University of Michigan and Masters Business Admin degree from Kellogg School of Management.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 20/06/2023 | 3 000 ( 0,01% ) | 33 450 $ | 31/03/2024 | |
MAXCYTE, INC.
-.--% | 22/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Rekha Hemrajani
| Sociétés | Poste | Début |
|---|---|---|
| ALX ONCOLOGY HOLDINGS INC. | Director/Board Member | 01/04/2020 |
| MAXCYTE, INC. | Director/Board Member | 15/06/2021 |
| Hemmo Pharma LLP | Director/Board Member | - |
ALX Oncology, Inc.
 ALX Oncology, Inc. Pharmaceuticals: MajorHealth Technology Part of ALX Oncology Holdings, Inc., ALX Oncology, Inc. operates as a clinical-stage immuno-oncology company which develops therapies for cancers. The private company is based in Burlingame, CA. The CEO of the company is Jaume Pons. | Director/Board Member | 04/05/2020 |
Hemmo Pharmaceuticals Pvt Ltd.
 Hemmo Pharmaceuticals Pvt Ltd. Pharmaceuticals: MajorHealth Technology Part of Piramal Pharma Ltd., Hemmo Pharmaceuticals Pvt Ltd. is an Indian company that develops and manufactures peptide APIs. The private company is based in Mumbai, India. The CEO of the company is Madhu Vikram Utamsingh. Hemmo Pharmaceuticals was acquired by Piramal Pharma Ltd. on June 22, 2021 for $105.61 million. | Director/Board Member | - |
BioAge Labs, Inc.
 BioAge Labs, Inc. BiotechnologyHealth Technology BioAge Labs, Inc. develops biological products. It offers data with machine learning to measure human aging and accelerate drug discovery. The company was founded by Kristen Fortney and is headquartered in Berkeley, CA. | Director/Board Member | 19/08/2021 |
Anciens postes connus de Rekha Hemrajani
| Sociétés | Poste | Fin |
|---|---|---|
| JIYA ACQUISITION CORP. | Chief Executive Officer | 01/11/2022 |
| ADVERUM BIOTECHNOLOGIES, INC. | Director/Board Member | 12/05/2021 |
| ARAVIVE, INC. | Chief Executive Officer | 08/04/2020 |
| ░░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
Formation de Rekha Hemrajani
| University of Michigan | Undergraduate Degree |
| Kellogg School of Management | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 8 |
|---|---|
| EXELIXIS, INC. | Health Technology |
| MAXCYTE, INC. | Health Technology |
| SAGIMET BIOSCIENCES INC. | Health Technology |
| ADVERUM BIOTECHNOLOGIES, INC. | Health Technology |
| RAPT THERAPEUTICS, INC. | Health Technology |
| ARCUS BIOSCIENCES, INC. | Health Technology |
| ARAVIVE, INC. | Health Technology |
| ALX ONCOLOGY HOLDINGS INC. | Health Technology |
| Entreprise privées | 7 |
|---|---|
Lehman Brothers, Inc.
 Lehman Brothers, Inc. Investment Banks/BrokersFinance A subsidiary of Lehman Brothers Holdings, Inc., Lehman Brothers, Inc. is a broker/dealer headquartered in New York City. They provide global equity and fixed research. The equity research department covers more than 100 sectors. They use a fundamental, quantitative, strategic and tactical research approach. In addition to these Lehman has also developed special products, such as 10 uncommon values and 10 uncommon eurovalues. | Finance |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Health Technology |
BioAge Labs, Inc.
BioAge Labs, Inc. BiotechnologyHealth Technology BioAge Labs, Inc. develops biological products. It offers data with machine learning to measure human aging and accelerate drug discovery. The company was founded by Kristen Fortney and is headquartered in Berkeley, CA. | Health Technology |
ALX Oncology, Inc.
ALX Oncology, Inc. Pharmaceuticals: MajorHealth Technology Part of ALX Oncology Holdings, Inc., ALX Oncology, Inc. operates as a clinical-stage immuno-oncology company which develops therapies for cancers. The private company is based in Burlingame, CA. The CEO of the company is Jaume Pons. | Health Technology |
Hemmo Pharmaceuticals Pvt Ltd.
Hemmo Pharmaceuticals Pvt Ltd. Pharmaceuticals: MajorHealth Technology Part of Piramal Pharma Ltd., Hemmo Pharmaceuticals Pvt Ltd. is an Indian company that develops and manufactures peptide APIs. The private company is based in Mumbai, India. The CEO of the company is Madhu Vikram Utamsingh. Hemmo Pharmaceuticals was acquired by Piramal Pharma Ltd. on June 22, 2021 for $105.61 million. | Health Technology |
Jiya Acquisition Corp.
 Jiya Acquisition Corp. Financial ConglomeratesFinance Jiya Acquisition Corp. is a blank check company. The firm was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. It focuses on identifying promising opportunities in the biopharmaceutical sector. The company was founded in August 2020 and is headquartered in Palo Alto, CA. | Finance |
| Hemmo Pharma LLP |
